Virpax Pharmaceuticals said that it has signed a cooperative research and development agreement (CRADA) for evaluation of the company's NobrXiol (VRP324) cannabidiol nasal powder in rodent models of epilepsy and seizures by the Epilepsy Therapy Screening Program (ETSP) of the National Institute of Neurological Disorders and Stroke, part of the National Institutes of … [Read more...] about Virpax announces that NIH group will conduct preclinical studies of NobrXiol intranasal CBD for the treatment of epilepsy
Business
Padagis announces submission of ANDA for generic of Kloxxado naloxone nasal spray
Padagis announced two recent ANDA submissions, including an ANDA for a generic version of Hikma's Kloxxado naloxone nasal spray for the reversal of opioid overdose. Kloxxado, which delivers an 8 mg dose of naloxone compared to a 4 mg dose for Narcan nasal spray, was approved by the FDA in April 2021. Padagis launched a generic version of Narcan in the US in June … [Read more...] about Padagis announces submission of ANDA for generic of Kloxxado naloxone nasal spray
Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Soft mist inhaler developer Resyca, a joint venture of Medspray Pharma and Recipharm, has announced the promotion of current Head of Development and Project Management Nicolas Buchmann to Chief Technical Officer. Buchman will take over from Wilbur de Kruijf, who is leaving to serve as CEO of a start-up inhaled drug developer called Thaerapy. Resyca also announced that … [Read more...] about Resyca announces new Chief Technical Officer, licensing deal with Thaerapy
Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS
Acadia Pharmaceuticals announced that it will develop ACP-101 (formerly LV-101) intranasal carbetocin for the treatment of excessive hunger in Prader-Willi syndrome (PWS). Acadia acquired the rights to the nasal spray when it acquired Levo Therapeutics in June 2022. Levo had licensed the intranasal carbetocin from Ferring Pharmaceuticals in 2017 and initiated Phase 3 … [Read more...] about Acadia Pharmaceuticals to develop intranasal carbetocin for the treatment of hyperphagia in PWS
Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine
Moat Biotechnology (MoatBio), a spin-out from Tetherex Pharmaceuticals, announced that it has closed a funding round of more than $6.5 million following an initial funding led by Cortado Ventures in September 2022. The company says that it intends to use the proceeds for continued development of an inhaled/intranasal COVID-19 vaccine based on the SC-AdVax single-cycle … [Read more...] about Moat Biotechnology raises $6.5 million for development of intranasal/inhaled COVID-19 vaccine
Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury
Alpha Cognition announced that the Army Medical Research and Material Command has awarded the company a $750,000 grant to support a pre-clinical study of the possible use of ALPHA-1062 Intranasal galantamine for the treatment of blast-induced mild traumatic brain injury (mTBI). According to Alpha Cognition, the study will be conducted in partnership with the Seattle … [Read more...] about Alpha Cognition gets $750,000 grant from US military for development of ALPHA-1062 intranasal galantamine for the treatment of brain injury
CQDM provides funding for Oragenics intranasal COVID-19 vaccine
According to Oragenics, Canadian biopharmaceutical research consortium CQDM has awarded a grant for development of variant-agnostic protein antigens for use in an intranasal COVID-19 vaccine that "aims to build upon Oragenics’ current lead intranasal vaccine candidate NT-CoV2-1." According to the CQDM web site, the total value of the project is $1.64 million, with … [Read more...] about CQDM provides funding for Oragenics intranasal COVID-19 vaccine
Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company's Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024. The company announced in … [Read more...] about Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced that if would begin manufacturing 0.5% albuterol in response to the shortage. Nephron notes that has been manufacturing … [Read more...] about Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company's PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the funds will go toward a Phase 2 trial titled, “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 … [Read more...] about Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution